Obesity drug maker Sciwind targets IPO, with heavyweight backers
Supported by Tencent and Meituan, the biotech aims to launch a targeted GLP-1 drug next year that could challenge established products, but it faces stiff competition Key Takeaways: • Clinical…
FAST NEWS: Structure Therapeutics Leaps in U.S. Trading Debut
The latest: Innovative drug developer Structure Therapeutics Inc. (GPCR.US) made its IPO trading debut last Friday, becoming the first major U.S. listing by a Chinese company this year.Looking up: The company…
RELATED ARTICLES
-
Hengrui Pharma targets obesity drug launch after test success
1278.HK 600276.SHG - RNA drug developer Ribo Life targets fresh funding channel
-
Medtide launches IPO to bulk up its weight-loss business
3880.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
- Will Trump’s drug order put the brakes on China’s overseas pharma drive?
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
